| Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA DB Finlay*, JJ Manning*, MS Ibsen, CE Macdonald, M Patel, JA Javitch, ... ACS chemical neuroscience 10 (10), 4350-4360, 2019 | 59 | 2019 |
| Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists M Patel, JJ Manning, DB Finlay, JA Javitch, SD Banister, NL Grimsey, ... Biochemical Pharmacology 175, 113871, 2020 | 57 | 2020 |
| CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist RC Kevin, L Anderson, IS McGregor, R Boyd, JJ Manning, M Glass, ... Frontiers in Pharmacology 10, 595, 2019 | 39 | 2019 |
| Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias JJ Manning, HM Green, M Glass, DB Finlay Neuropharmacology 193, 108611, 2021 | 34 | 2021 |
| Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1, 8-naphthyridin-2-(1 H)-one-3-carboxamide scaffold AG Cooper, CRM Oyagawa, JJ Manning, S Singh, S Hook, NL Grimsey, ... Medchemcomm 9 (12), 2055-2067, 2018 | 22 | 2018 |
| The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F‐PY‐PICA, 5F‐PY‐PINACA, and their analogs SD Banister, RC Kevin, L Martin, A Adams, C Macdonald, JJ Manning, ... Drug Testing and Analysis 11 (7), 976-989, 2019 | 21 | 2019 |
| Exploring stereochemical and conformational requirements at cannabinoid receptors for synthetic cannabinoids related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA A Ametovski, C Macdonald, JJ Manning, SAS Haneef, M Santiago, ... ACS Chemical Neuroscience 11 (21), 3672-3682, 2020 | 19 | 2020 |
| Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1 … J Markham, E Sparkes, R Boyd, S Chen, JJ Manning, D Finlay, F Lai, ... ACS Chemical Neuroscience 13 (8), 1281-1295, 2022 | 10 | 2022 |
| Cannabinoid 1 (CB1) receptor arrestin subtype‐selectivity and phosphorylation dependence JJ Manning, G Rawcliffe, DB Finlay, M Glass British Journal of Pharmacology 180 (3), 369-382, 2023 | 9 | 2023 |
| Promiscuous G-protein activation by the calcium-sensing receptor H Zuo, J Park, A Frangaj, J Ye, G Lu, JJ Manning, WB Asher, Z Lu, GB Hu, ... Nature, 2024 | 8 | 2024 |
| Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors RC Kevin, S Mirlohi, JJ Manning, R Boyd, EA Cairns, A Ametovski, F Lai, ... ACS Chemical Neuroscience 13 (9), 1395-1409, 2022 | 6 | 2022 |
| A novel “activation switch” motif common to all aminergic receptors KH Lee, JJ Manning, J Javitch, L Shi Journal of Chemical Information and Modeling, 2023 | 5 | 2023 |
| Methods for automating the analysis of live-cell single-molecule FRET data J Meszaros, P Geggier, JJ Manning, WB Asher, JA Javitch Frontiers in Cell and Developmental Biology 11, 1184077, 2023 | 3 | 2023 |
| Positive allosteric modulation of the cannabinoid CB1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics HM Green, JJ Manning, IR Greig, RA Ross, DB Finlay, M Glass British Journal of Pharmacology, 2024 | 2 | 2024 |
| Exploring the Requirements for Arrestin Translocation to the Cannabinoid Type-1 Receptor JJ Manning The University of Otago, 2022 | 1 | 2022 |
| GPCR kinase subtype requirements for arrestin-2 and-3 translocation to the cannabinoid CB1 receptor and the consequences on G protein signalling JJ Manning, DB Finlay, M Glass Biochemical pharmacology 224, 116190, 2024 | | 2024 |